How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,627 results for

Chronic Hepatitis B Carrier

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection. (PubMed)

Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection. Despite an available vaccine and efficient treatment for hepatitis B virus (HBV) infection, chronic HBV infection still remains a major global threat, and one of the top 20 causes of human mortality worldwide. One of the major challenges in controlling HBV infection is the high number of undiagnosed chronic carriers and the lack of access to prophylaxis and treatment in several parts of the world. We (...) of viral hepatitis a global health priority.© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Full Text available with Trip Pro

2017 Liver International

182. Ten Things You Should Know About Hepatitis B and Do in 2017

just discovered you have chronic hepatitis B, which you may have contracted at birth, you need to tell your siblings and your mother and get them screened and immunized if needed. Dating someone, and about to take the next step? You need to disclose ahead of time and give them information and choices. It builds trust and it’s the right thing to do. You would want the same for yourself. For more on disclosure click . Happy 2017! Our hope for a cure continues. As of January 2017, TAF has been (...) a good doctor in japan. if possible please give me some suggestions . Thank you Hello: The Hepatitis B Foundation has a list of liver specialists around the world. Please search for a doctor near you in Japan at: Good luck. Hi Robin Will u please tell me how u reached japan when you r in carrier stage.and what medicine u got from bangladeshi doctor. Thank u When is cure coming? Hello: Not soon enough, but experts around the world are far closer to finding a cure than ever. They predict they will find

2017 hepbblog

183. Facing the Threat of Hepatitis B Following Sexual Coercion or Assault

liver damage, which is indicated by a liver enzyme test for SGPT or ALT in your blood. The best thing you can do for yourself is eat healthy food, avoid alcohol and cigarettes, and get monitored regularly. We are optimistic that in the next few years a cure for hepatitis B will be developed. To keep up to date with the latest in drug developments, please visit our Drug Watch page at: Good luck. Can we get job as a resident doctor in Usa with chronic carrier status ,,,? Hello: Yes you can, the CDC (...) of sexual violence that spreads trauma, fear and diseases such as hepatitis B. However we can, whenever we can, we must work to make a difference. Post navigation Comments on this blog are closed. If you have questions about hepatitis B or this blog post, please email or call 215-489-4900. 13 thoughts on “Facing the Threat of Hepatitis B Following Sexual Coercion or Assault” says: We need more awareness and ways to have people vaccinated against this disease Iam hbv carrier and I vaccinated all three

2017 hepbblog

184. Genome-wide association study identifies a new locus at 7q21.13 associated with hepatitis B virus-related hepatocellular carcinoma. (PubMed)

Genome-wide association study identifies a new locus at 7q21.13 associated with hepatitis B virus-related hepatocellular carcinoma. Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. In China, chronic hepatitis B virus (HBV) infection remains the major risk factor for HCC. In this study, we performed a genome-wide association study (GWAS) among Chinese populations to identify novel genetic loci contributing to susceptibility to HBV-related HCC.Experimental (...) Design: GWAS scan is performed in a collection of 205 HBV-related HCC trios (each trio includes an affected proband and his/her both parents), and 355 chronic HBV carriers with HCC (cases) and 360 chronic HBV carriers without HCC (controls), followed by two rounds of replication studies totally consisting of 3,796 cases and 2,544 controls.Results: We identified a novel association signal within the CDK14 gene at 7q21.13 (index rs10272859, OR = 1.28, P = 9.46 × 10-10). Furthermore, we observed

2017 Clinical Cancer Research

185. Immunopathogenesis of Hepatitis B Virus. (PubMed)

Immunopathogenesis of Hepatitis B Virus. Chronic hepatitis B virus (HBV) infection is a global public health issue. There are >250 million people chronically infected with HBV, and these chronic carriers are at high risk of developing end-stage liver diseases and hepatocellular carcinoma. Patients with chronic hepatitis B (CHB) usually acquire the virus perinatally, while most patients infected during adulthood develop acute hepatitis B (AHB), which usually results in viral clearance. HBV

Full Text available with Trip Pro

2017 Journal of Infectious Diseases

186. MKSAP: 25-year-old man positive for hepatitis B surface antigen

management? A. Administration of hepatitis B vaccine B. Administration of pegylated interferon C. Administration of tenofovir D. α-Fetoprotein measurement every 12 months E. Ultrasound imaging of the liver every 6 months MKSAP Answer and Critique The correct answer is E. Ultrasound imaging of the liver every 6 months. The most appropriate management is ultrasound imaging of the liver every 6 months. This patient from Africa has evidence of chronic hepatitis B virus (HBV) infection. In approximately 50 (...) MKSAP: 25-year-old man positive for hepatitis B surface antigen Screening and surveillance for hepatocellular carcinoma MKSAP: 25-year-old man positive for hepatitis B surface antigen | | December 2, 2017 13 Shares Test your medicine knowledge with the , in partnership with the . A 25-year-old man is evaluated in follow-up after recently testing positive for hepatitis B surface antigen. He underwent testing as part of the immigration process from Somalia. Two other siblings also have hepatitis

2017 KevinMD blog

187. Bendamustine (Levact): increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation

should: monitor patients for respiratory signs and symptoms throughout treatment advise patients to report new signs of infection, including fever or respiratory symptoms promptly consider discontinuing bendamustine if there are signs of opportunistic infections Hepatitis B virus reactivation Reactivation of hepatitis B virus in chronic carriers of the virus has been reported after bendamustine. Some cases resulted in acute hepatic failure or a fatal outcome. Closely monitor carriers of hepatitis B (...) : Therapeutic area: , , Contents Advice for healthcare professionals: advise patients to report promptly new signs of infection, including fever or respiratory symptoms, and consider discontinuing bendamustine if there are signs of opportunistic infections monitor patients for opportunistic infections as well as cardiac, neurological, and respiratory adverse events hepatitis B virus (HBV) reactivation has also been reported; monitor known carriers of HBV for signs and symptoms of active HBV infection

Full Text available with Trip Pro

2017 MHRA Drug Safety Update

188. Alternative splicing of Hepatitis B virus: a novel virus/host interaction altering liver immunity. (PubMed)

expression was confirmed and maintained in a whole HBV context. Finally, viral spliced RNA detection related to a decrease of CCL2 expression in the livers of HBV chronic carriers underscored this mechanism.The microenvironment, modified by liver injury, increased HBSP RNA expression through splicing factor regulation, which in turn controlled hepatocyte chemokine synthesis. This feedback mechanism provides a novel insight into liver immunopathogenesis during HBV infection. Lay summary: Hepatitis B virus (...) Alternative splicing of Hepatitis B virus: a novel virus/host interaction altering liver immunity. Hepatitis B virus (HBV) RNA can undergo alternative splicing, but the relevance of this post-transcriptional regulation remains elusive. The mechanism of HBV alternative splicing regulation and its impact on liver pathogenesis were investigated.HBV RNA-interacting proteins were identified by RNA pull-down, combined with mass spectrometry analysis. HBV splicing regulation was investigated

Full Text available with Trip Pro

2017 Journal of Hepatology

189. Learn Which Cancer, Arthritis or Asthma Drugs Can Reactivate Hepatitis B – Even If You’ve Cleared the Infection

not mention (to) my oncologist that I was a carrier of hepatitis B, (because) I knew that it was not active. Then, after a week of chemo, I was really sick and got a high temperature. Then, my blood test came back (indicating) that my hepatitis B was reactivated. My liver doctor gave me medicine (an antiviral) to take to deactivate the virus.” Her oncologist immediately stopped chemotherapy and monitored her HBV DNA (viral load) and liver enzymes (ALT/SGPT) to make sure the antiviral lowered her viral (...) your hepatitis B and require monitoring and preventive use of antivirals to reduce reactivation risk, according to American Gastroenterological Association (AGA) : High-risk Drugs: More than 10 percent of people with current or resolved hepatitis B infections will experience a dangerous reactivation if treated with: Rituximab for non-Hodgkins lymphoma, or Ofatumumab for chronic lymphocytic leukemia Anyone with a current infection (HBsAg positive) treated with the following is also at high risk

2017 hepbblog

190. Association of Single Nucleotide Polymorphisms in MicroRNAs with Susceptibility to Hepatitis B Virus Infection and HBV-related Liver Complications: A Study in a Saudi Arabian Population. (PubMed)

Association of Single Nucleotide Polymorphisms in MicroRNAs with Susceptibility to Hepatitis B Virus Infection and HBV-related Liver Complications: A Study in a Saudi Arabian Population. The aim of this study was to evaluate the association of 10 SNPs in different microRNAs (miRNAs) with susceptibility to hepatitis B virus (HBV) infection, HBV clearance, persistence of chronic HBV infection, and progression to liver cirrhosis and hepatocellular carcinoma (HCC). Patients were categorized (...) into the following groups: inactive HBV carrier, active HBV carrier, HBV-cleared subject and cirrhosis+HCC. Samples were analysed for 10 SNPs in microRNAs using either PCR-based genotyping or the TaqMan assay. We found that rs1358379 was associated with susceptibility to HBV infection, HBV clearance, persistent chronic HBV infection and liver cirrhosis+HCC. In addition, we found that rs2292832 and rs11614913 were associated with risk of HBV infection, viral clearance and cirrhosis+HCC, whereas rs2910164

Full Text available with Trip Pro

2017 Journal of viral hepatitis

191. Genome-wide association analysis identifies a GLUL haplotype for familial hepatitis B virus-related hepatocellular carcinoma. (PubMed)

Genome-wide association analysis identifies a GLUL haplotype for familial hepatitis B virus-related hepatocellular carcinoma. A family history of liver cancer increases the risk of developing hepatocellular carcinoma (HCC) by 2-fold to 10-fold among patients with chronic hepatitis B virus (HBV). Previous genome-wide association studies have identified many possible susceptible loci associated with sporadic HBV-related HCC. However, despite family history being a well-known risk factor for HBV (...) -related HCC, to the authors' knowledge its genetic mechanisms and associating loci remain largely unknown or unexplored, most likely due to the relative rarity of familial HCC and the difficulty of sample collection.The authors conducted a genome-wide association study with 139 male cases with familial HBV-related HCC and 139 non-HCC male controls with chronic HBV. The results were corroborated further with an independent cohort of 101 patients with familial HBV-related HCC and comparison with both

2017 Cancer

192. Evaluation of the G145R Mutant of the Hepatitis B Virus as a Minor Strain in Mother-to-Child Transmission. (PubMed)

were born to HBV carrier mothers and became HBV carriers despite immnoprophylaxis (n = 25). The control cohort consisted of HBV carriers who had no history of receiving the hepatitis B vaccine, hepatitis B immunoglobulin or antiviral treatment (n = 126). The pregnant cohort comprised pregnant women with chronic HBV infection (n = 31). In the breakthrough cohort, 6 showed positive PCR results (major, 2; minor, 4). In the control cohort, 13 showed positive PCR results (major, 0; minor, 13). HBeAg (...) Evaluation of the G145R Mutant of the Hepatitis B Virus as a Minor Strain in Mother-to-Child Transmission. The role of the hepatitis B virus (HBV) mutant G145R, with a single change in amino acid 145 of the surface protein, as a minor population remains unknown in mother-to-child transmission. The minor strain as well as the major strain of the G145R mutant were evaluated in three cohorts using a locked nucleic acid probe-based real-time PCR. The breakthrough cohort consisted of children who

Full Text available with Trip Pro

2016 PLoS ONE

193. Time to End the Military’s Ban on Enlistees with Hepatitis B

discovered they have hepatitis B. This military code historically barred people with serious medical conditions because they were considered unfit to serve, suspected to incur high healthcare costs and could pose an infection risk to fellow soldiers. The code prohibits enlistees with the, “Presence of … current acute or chronic hepatitis carrier state, hepatitis in the preceding six months or persistence of symptoms after six months, or objective evidence of impairment of liver function.” But most people (...) Time to End the Military’s Ban on Enlistees with Hepatitis B Time to End the Military's Ban on Enlistees with Hepatitis B - Hepatitis B Foundation , Time to End the Military’s Ban on Enlistees with Hepatitis B Image courtesy of vectorolie at FreeDigitalPhotos.net. By Christine Kukka One of the most glaring civil rights abuses facing people with hepatitis B in the United States today is the military’s continued refusal to allow anyone with chronic hepatitis B to enlist. This prohibition

2017 hepbblog

194. Elimination of Hepatitis B: Is It a Mission Possible? (PubMed)

-to-infant transmission in pregnant women with a high viral load. For patients with chronic HBV infection, quantitative hepatitis B surface antigen is a useful tool to define inactive carriers and to guide antiviral therapy. Quantification of HBV mutants is also useful in predicting long-term outcomes more precisely than ever. The next challenge is how to achieve an HBV cure; although immunotherapy is a promising strategy, the current results from two clinical trials using therapeutic vaccines to induce (...) Elimination of Hepatitis B: Is It a Mission Possible? Chronic hepatitis B virus (HBV) infection is a global public health issue. Although the disease cannot be cured effectively, disease management has been improved over the past decade. The introduction of potent nucleos(t)ide analogues (NAs) to suppress viral replication represented a giant leap in the control of this disease. It has been shown that tenofovir treatment, a potent NA, complements current immunoprophylaxis to diminish mother

Full Text available with Trip Pro

2017 BMC Medicine

195. Long term outcome of Inactive and Active, Low Viremic HBeAg negative Hepatitis B Virus infection: benign course towards HBsAg clearance. (PubMed)

Long term outcome of Inactive and Active, Low Viremic HBeAg negative Hepatitis B Virus infection: benign course towards HBsAg clearance. The difference between the long-term outcome of low-viraemic (HBV-DNA≤20 000-IU/mL, LV-AC) and inactive HBsAg carriers (HBV-DNA≤2000-IU/mL, IC) remains to be defined. We studied prospectively 153 HBeAg-negative HBsAg-carriers with baseline HBV-DNA≤20 000-IU/mL and normal transaminases.IC, LV-AC or chronic hepatitis B (CHB) (HBV-DNA persistently ≤2000-IU/mL (...) , ≤20 000-IU/mL or >20 000-IU/mL respectively) were diagnosed after 1-year, 3-monthly monitoring. Thereafter IC and LV-AC were followed-up for additional 57.2 (8.5-158.3) months. HBV-DNA, HBsAg, HBV"core-related"Antigen (HBcrAg) and total-anti-HBc were quantified at baseline.After the 1st year diagnostic follow-up CHB [higher HBV-DNA (P=.005), total-anti-HBc (P=.012), ALT (P=.007) and liver-stiffness (P=.021)] was identified in 20 (13.1%) carriers; baseline HBsAg≤1000IU/HBV-DNA≤2000IU/mL excluded

2017 Liver International

196. Overt and occult hepatitis B virus infection among community children in Northwest China. (PubMed)

Overt and occult hepatitis B virus infection among community children in Northwest China. Although a universal newborn hepatitis B (HB) immunization programme has been implemented in China, hepatitis B virus (HBV) breakthrough infection, including HB surface antigen (HBsAg)-positive infection and occult HBV infection (OBI), still occurs during infancy or childhood. Obtaining the actual prevalence of HBV infection in general children is important for preventing and controlling the spread of HB (...) . Accordingly, we investigated the prevalence of overt infection and OBI in community children and compared the serological and virological characteristics of OBI and HBsAg carrier children to clarify the mechanisms related to OBI. In total, 6 706 community children <12 years of age were included from a population-based HBV seroepidemiological investigation in Northwest China. The HBsAg carrier rate in community children was 1.60% (107/6706), and the anti-HBs positive rate was 57.35% (3846/6706

2017 Journal of viral hepatitis

197. A critical role of hepatitis B virus polymerase in cirrhosis, hepatocellular carcinoma, and steatosis (PubMed)

A critical role of hepatitis B virus polymerase in cirrhosis, hepatocellular carcinoma, and steatosis Hepatitis B is one of the most common infectious diseases in the world; more than 350 million people are carriers of hepatitis B virus (HBV). Chronic HBV infection (CHB) leads to liver diseases such as cirrhosis, hepatocellular carcinoma (HCC), and steatosis. Despite its seriousness in terms of public health, the pathogenic mechanism of how CHB leads to liver diseases, especially cirrhosis

Full Text available with Trip Pro

2017 FEBS open bio

198. Heparin at physiological concentration can enhance PEG-free in vitro infection with human hepatitis B virus (PubMed)

Heparin at physiological concentration can enhance PEG-free in vitro infection with human hepatitis B virus Hepatitis B virus (HBV) is a blood-borne pathogen responsible for chronic hepatitis, cirrhosis, and liver cancer. The mechanism of HBV entry into hepatocytes remains to be investigated. Recently, sodium taurocholate cotransporting polypeptide (NTCP) was discovered as a major HBV receptor based on an in vitro infection system using NTCP-reconstituted HepG2 cells. However, this infection (...) . This system based on the HepG2-NTCP-AS cells can support in vitro infection with HBV genotypes B and C, as well as using serum samples from HBeAg positive and negative chronic carriers. In summary, our study provides a PEG-free infection system closely resembling human natural infection. In addition, it points to a future research direction for heparin and heparin-binding host factor(s) in the blood, which are potentially involved in viral entry. To our knowledge, this is the first soluble and circulatory

Full Text available with Trip Pro

2017 Scientific reports

199. Hepatitis B virus (HBV) X gene mutations and their association with liver disease progression in HBV-infected patients (PubMed)

Hepatitis B virus (HBV) X gene mutations and their association with liver disease progression in HBV-infected patients Hepatitis B virus (HBV) is one of the most widespread human pathogens causing chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). This study investigated the clinical impact of single and combinational mutations in HBx gene on the pathogenesis of HCC during progressive stages of liver disease. The patients were categorized into inactive HBV carriers, active (...) carriers, cirrhosis and HCC groups based on disease severity. Male sex, age > 50 years, and high serum alanine aminotransferase level were associated with risk of progressive liver disease. I127T, V131I, and F132Y/I/R mutations showed a significant increasing trend associated with the disease progression to HCC. H94Y and K130M mutations were also significantly associated with severe liver disease. One double mutation (K130M+V131I) and two triple mutations (I127T+K130M+V131L and K130M+V131I+F132Y) were

Full Text available with Trip Pro

2017 Oncotarget

200. Classification and sensitivity analysis of the transmission dynamic of hepatitis B (PubMed)

Classification and sensitivity analysis of the transmission dynamic of hepatitis B Hepatitis B infection caused by the hepatitis B virus is one of the most serious viral infections and a global health problem. In the transmission of hepatitis B infection, three different phases, i.e. acute infected, chronically infected, and carrier individuals, play important roles. Carrier individuals are especially significant, because they do not exhibit any symptoms and are able to transmit the infection (...) . Here we assessed the transmissibility associated with different infection stages of hepatitis B and generated an epidemic model.To demonstrate the transmission dynamic of hepatitis B, we investigate an epidemic model by dividing the infectious class into three subclasses, namely acute infected, chronically infected, and carrier individuals with both horizontal and vertical transmission.Numerical results and sensitivity analysis of some important parameters are presented to show that the proportion

Full Text available with Trip Pro

2017 Theoretical biology & medical modelling

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>